Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 10426772
Use of ergot alkaloids as an anthelmintic agent
granted -
US 10428082
Triazole derivatives of melampomagnolide B and methods of use thereof
granted -
US 10426786
Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
granted -
US 10428352
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 10428143
Modulation of stimulatory and non-stimulatory myeloid cells
granted -
US 10426799
Methods for production of platelets from pluripotent stem cells and compositions thereof
granted -
US 10428115
Dynorphin A analogs with bradykinin receptors specificity for modulation of neuropathic pain
granted -
US 10428159
Blocking monoclonal antibodies to AGR2 and its receptor C4.4A
granted -
US 10428057
Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease
granted -
US 10420720
Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
granted -
US 10420751
Methods of treating inflammatory bowel disease with AMD3100 and tacrolimus
granted -
US 10420758
Indolinyl-sulfonamide inhibitors of tankyrase and methods of use thereof
granted -
US 10422004
Diagnostic method for distinguishing forms of esophageal eosinophilia
granted -
US 10420918
Compositions and methods for reducing traumatic edema of the central nervous system
granted -
US 10421980
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 10421773
Bone-selective osteogenic oxysterol bisphosphonate analogs
granted -
US 10421722
Sulfur-containing compounds targeting vesicular acetylcholine transporter
granted -
US 10420813
Competitive inhibitors of invariant chain expression and/or ectopic clip binding
granted -
US 10421765
Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase
granted -
US 10420833
Combinatorial platform for the display of surface adjuvants and antigens
granted -
US 10416163
Method and treatment of recurring endometrial cancer with an inhibitor of USP14
granted -
US 10415040
Nucleic acid amphiphiles and nanostructures
granted -
US 10416174
Diagnosis and prognosis for chronic fatigue syndrome
granted -
US 10413620
Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
granted -
US 10414725
Pyrrolomycins and methods of using the same
granted -
US 10413577
Compositions and methods for promoting growth of beneficial microbes to treat or prevent disease or prolong life
granted -
US 10413602
Fungal immunogens and related materials and methods
granted -
US 10413603
Compositions, methods and uses for improved human papilloma virus constructs
granted -
US 10415061
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 10407484
Compositions and methods for modulating T-cell mediated immune response
granted -
US 10406225
Anti-EphA2 antibodies and methods of use thereof
granted -
US 10406169
Methods of monitoring estriol therapy
granted -
US 10407495
Bispecific antibody fragments for neurological disease proteins and methods of use
granted -
US 10407503
Fully human antibodies and fragments recognizing human c-Met
granted -
US 10407697
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 10407735
Schlap-1 ncRNA and uses thereof
granted -
US 10407488
Therapy for treatment or prevention of conditions associated with bleeding or hypocoagulation
granted -
US 10406248
Molecular imaging of cancer cells in vivo
granted -
US 10407374
Compositions and methods for ameliorating CNS inflammation, psychosis, delirium, PTSD or PTSS
granted -
US 10406214
Propionyl-CoA carboxylase compositions and uses thereof
granted -
US 10406233
Telodendrimers with enhanced drug delivery
granted -
US 10406167
Texaphyrin-Pt(IV) conjugates and compositions for use in overcoming platinum resistance
granted -
US 10407457
Pyrrolopyrimidine nucleosides and analogs thereof
granted -
US 10398749
Methods of treating muscular dystrophy
granted -
US 10398680
Methods of treating muscular dystrophy
granted -
US 10398668
Glutamate treatment of cardiovascular disorders
granted -
US 10400006
Estrogen receptor modulators
granted -
US 10400225
TAL effector-mediated DNA modification
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory